Myriad IPO
This article was originally published in The Gray Sheet
Executive Summary
Proteomics collaboration with Hitachi and Oracle to identify drug targets is prepping to go public, according to the firm. Collaborators on the project, which is currently dubbed Myriad Proteomics, are waiting for amenable market conditions to launch an initial public offering. The operation, including a fully functioning data-generating facility in Salt Lake City with a 65-member staff, was launched in 2001 to compete with Celera Genomics (1"The Gray Sheet" April 23, 2001, In Brief). Myriad contributed $82 mil. in technology to the alliance, retaining a 50% stake in the $185 mil. venture...